Additionally, the development of progressive fibrosing pathology influenced TGFB3 expression, which was higher in SSc-ILD patients with this complication (0.0073 ± 0.0176 vs. 0.0009 ± 0.0006, p = 0.024, Table 2). This evidence concerns the gene TGFB3 and systemic sclerosis.